European journal of pharmacology · 2025
The effect of indobufen and aspirin on platelet function in acute ischemic stroke patients with early neurological deterioration.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xu Shu, Jiang Zihe, Zhou Yin, Cao Lidan, Zhang Yan
Аннотация
PURPOSE: This study aimed to compare the effects of indobufen and aspirin on platelet function, neurological recovery, and adverse reactions in acute ischemic stroke patients with early neurological deterioration.
METHODS: A total of 250 patients were randomized into two groups (indobufen group, n = 125; aspirin group, n = 125). Platelet function was assessed using Arachidonic Acid - Platelet Aggregation Ratio (AA-PAR), ADP - Platelet Aggregation Ratio (ADP-PAR0, Thromboxane B2 (TXB2) concentrations, and other hematological parameters. Neurological function was evaluated using MIESSS/NIHSS and mRS scores at 10 days, 3 months, and 1 year post-treatment. Adverse reactions were recorded during follow-up.
RESULTS: The indobufen group showed significantly lower AA-PAR and ADP-PAR levels, as well as reduced TXB2 concentrations compared to the aspirin group, indicating stronger platelet inhibition. Neurological assessments revealed better early and long-term recovery in the indobufen group, with significantly lower MIESSS/NIHSS and mRS scores at all time points. Regarding adverse reactions, the indobufen group exhibited a significantly lower incidence of gastrointestinal discomfort (10.00 % vs. 16.30 %, P = 0.03), though the incidence of bleeding events and renal dysfunction was similar between the groups.
CONCLUSION: Indobufen demonstrated superior platelet inhibition and more favorable neurological recovery compared to aspirin in acute ischemic stroke patients with early neurological deterioration. Indobufen also had a lower incidence of gastrointestinal side effects, while its overall safety profile was comparable to that of aspirin.
METHODS: A total of 250 patients were randomized into two groups (indobufen group, n = 125; aspirin group, n = 125). Platelet function was assessed using Arachidonic Acid - Platelet Aggregation Ratio (AA-PAR), ADP - Platelet Aggregation Ratio (ADP-PAR0, Thromboxane B2 (TXB2) concentrations, and other hematological parameters. Neurological function was evaluated using MIESSS/NIHSS and mRS scores at 10 days, 3 months, and 1 year post-treatment. Adverse reactions were recorded during follow-up.
RESULTS: The indobufen group showed significantly lower AA-PAR and ADP-PAR levels, as well as reduced TXB2 concentrations compared to the aspirin group, indicating stronger platelet inhibition. Neurological assessments revealed better early and long-term recovery in the indobufen group, with significantly lower MIESSS/NIHSS and mRS scores at all time points. Regarding adverse reactions, the indobufen group exhibited a significantly lower incidence of gastrointestinal discomfort (10.00 % vs. 16.30 %, P = 0.03), though the incidence of bleeding events and renal dysfunction was similar between the groups.
CONCLUSION: Indobufen demonstrated superior platelet inhibition and more favorable neurological recovery compared to aspirin in acute ischemic stroke patients with early neurological deterioration. Indobufen also had a lower incidence of gastrointestinal side effects, while its overall safety profile was comparable to that of aspirin.